Kymera Therapeutics to Participate in Upcoming November Investor Conferences

Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR) has announced its participation in several major healthcare investor conferences this November. The company will engage in fireside chats at the Guggenheim Inaugural Healthcare Innovation Conference in Boston, Stifel 2024 Healthcare Conference in New York, Wolfe Research Healthcare Conference in New York, and Jefferies London Healthcare Conference in London. Additionally, they will attend the J.P. Morgan Equity Opportunities Forum in Miami for one-on-one meetings. Live webcasts of the presentations will be available on the company's website under the Investors section, with replays accessible after the events.

WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:

• Guggenheim Inaugural Healthcare Innovation Conference in Boston, MA on November 12 at 10:00 a.m. ET;
• J.P. Morgan Equity Opportunities Forum in Miami, FL on November 14, one-on-one meetings only;
• Stifel 2024 Healthcare Conference in New York, NY on November 18 at 11:30 a.m. ET;
• 6^th Annual Wolfe Research Healthcare Conference in New York, NY on November 19 at 9:20 a.m. ET; and
• Jefferies London Healthcare Conference in London, UK on November 20 at 4:00 p.m. GMT.
  

Live webcasts of the presentations will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. Replays of the webcasts will be archived and available following the events.

About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.

Investor and Media Contact:  

Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300 

FAQ

What investor conferences is Kymera Therapeutics (KYMR) attending in November 2024?

Kymera Therapeutics is attending five major conferences: Guggenheim Healthcare Innovation Conference (Boston), J.P. Morgan Equity Opportunities Forum (Miami), Stifel Healthcare Conference (New York), Wolfe Research Healthcare Conference (New York), and Jefferies London Healthcare Conference.

Where can I watch Kymera Therapeutics (KYMR) November 2024 conference presentations?

Live webcasts of Kymera's presentations will be available in the Investors section under 'News and Events' at www.kymeratx.com, with replays archived for later viewing.

What time is Kymera Therapeutics (KYMR) presenting at the Guggenheim Healthcare Conference?

Kymera Therapeutics is scheduled to present at the Guggenheim Inaugural Healthcare Innovation Conference on November 12 at 10:00 a.m. ET.

Will Kymera Therapeutics (KYMR) be presenting at the J.P. Morgan Forum in November 2024?

No, Kymera Therapeutics will only be conducting one-on-one meetings at the J.P. Morgan Equity Opportunities Forum in Miami on November 14, with no formal presentation scheduled.